SarcomaSARCOPALLNCT07532668
Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma
An observational study of Sarcoma, run by Centre Leon Berard at 1 site in France.
Trial summary
The goal of this observational study is to describe palliative pathways in adult patients who died from their sarcoma. The main question it aims to answer is: How patients who died from sarcoma are followed by palliative team. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sarcoma
- How many people
- 207 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2024to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All patients with sarcoma follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie who died in 2024
Who may be able to join
- Oncology follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie
- sarcoma histology confirmed
- >18 years at diagnosis
- death between 01/01/2024 ans 31/12/2024
- death related to sarcoma
Who cannot join
- >1 year between last follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie and death
- patient opposed to the collect of data
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this observational study is to describe palliative pathways in adult patients who died from their sarcoma.
The main question it aims to answer is:
How patients who died from sarcoma are followed by palliative team.
- Conditions
- Sarcoma
- Keywords
- sarcoma, palliative care, aggressivness of care, cancer, end of life
- Medical subject headings
- Sarcoma, Neoplasms, Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| adult patients who died from sarcoma with >1 agressivness near the end of life criteria | Not described | |
| adult patients who died from sarcoma with 0-1 agressivness near the end of life criteria | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Palliative pathways of patients who died from sarcoma
Palliative pathways will be described using the proportion of patients with each of the following component :
- hospitalisation in a palliative care unit,
- consultation with palliative care doctor,
- mobile palliative care team advice We collect data on the first and last time of each kind of palliative follow up, we collect the number of day between the meeting and death For exemple: palliative care unit: first meeting 200 days before death and last meeting 80 days before death
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
Secondary outcomes (7)
Treatment with chemotherapy in the last 14 days of life
Percentage and number of patients having a treatment with chemotherapy in the last 14 days of life
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
More than 1 visit in an emergency unit in the last 30 days of life
Percentage and number of patients having more than 1 visit in an emergency unit in the last 30 days of life
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
Hospitalization in a resuscitation unit in the last 30 days of life
Percentage and number of patients having a hospitalization in a resuscitation unit in the last 30 days of life
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
More than 1 hospitalization in the last 30 days of life
Percentage and number of patients having more than 1 hospitalization in the last 30 days of life
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
Less than 3 days in palliative care unit
Percentage and number of patients having a hospitalization in a palliative care unit less than three days before death
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
New chemotherapy regimen starting in the last 30 days of life
Percentage and number of patients having a new chemotherapy regimen starting in the last 30 days of life
Measured: From date of inclusion until the date of death from any cause, assessed up to 42 months
Place of death
Hospital and type of unit or home will be described
Measured: At the date of death from any cause, assessed up to 42 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2026
- Study start1 Jan 2024
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcomaStudies of the same condition, open and under way.
- More trials run by Centre Leon BerardThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 207 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Leon Berard
- Sponsor type
- University, hospital or other
- Collaborators
- Institut Curie, Gustave Roussy, Cancer Campus, Grand Paris
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07532668
- Sponsor's protocol ID
- ET25-182 (SARCOPALL)
- Acronym
- SARCOPALL
- Status last verified
- Apr 2026
- First submitted
- 25 Mar 2026
- Last updated
- 16 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual Participant Data must not be shared according to the local regulation
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma
- ClinicalTrials.gov ID
- NCT07532668
- Acronym / sponsor ID
- SARCOPALL / ET25-182 (SARCOPALL)
- Conditions
- Sarcoma
- Keywords
- sarcoma, palliative care, aggressivness of care, cancer, end of life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 207 participants (actual)
- Lead sponsor
- Centre Leon BerardUniversity, hospital or other
- Collaborators
- Institut Curie, Gustave Roussy, Cancer Campus, Grand Paris
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 16 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to describe palliative pathways in adult patients who died from their sarcoma.
The main question it aims to answer is:
How patients who died from sarcoma are followed by palliative team.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| adult patients who died from sarcoma with >1 agressivness near the end of life criteria | – | – |
| adult patients who died from sarcoma with 0-1 agressivness near the end of life criteria | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients with sarcoma follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie who died in 2024
Key inclusion criteria (5 listed)
- Oncology follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie
- sarcoma histology confirmed
- >18 years at diagnosis
- death between 01/01/2024 ans 31/12/2024
- death related to sarcoma
Key exclusion criteria (2 listed)
- >1 year between last follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie and death
- patient opposed to the collect of data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Palliative pathways of patients who died from sarcoma
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Palliative pathways will be described using the proportion of patients with each of the following component : * hospitalisation in a palliative care unit, * consultation with palliative care doctor, * mobile palliative care team advice We collect data on the first and last time of each kind of palliative follow up, we collect the number of day between the meeting and death For exemple: palliative care unit: first meeting 200 days before death and last meeting 80 days before death
7 secondary outcomes
Treatment with chemotherapy in the last 14 days of life
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
More than 1 visit in an emergency unit in the last 30 days of life
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Hospitalization in a resuscitation unit in the last 30 days of life
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
More than 1 hospitalization in the last 30 days of life
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Less than 3 days in palliative care unit
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
New chemotherapy regimen starting in the last 30 days of life
Time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Place of death
Time frame: At the date of death from any cause, assessed up to 42 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Individual participant dataSharing planned: No. Individual Participant Data must not be shared according to the local regulation
Related trials for Sarcoma
RecruitingPhase 2
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
Soft Tissue Sarcoma
RecruitingPhase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Lymphoma, Waldenström Macroglobulinemia (WM)
Enrolling by invitationPhase 1
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
Soft Tissue Sarcoma, Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcoma, run by Centre Leon Berard at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Palliative pathways of patients who died from sarcoma (time frame: From date of inclusion until the date of death from any cause, assessed up to 42 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.